What is the current Metagenomics in Healthcare market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Metagenomics in Healthcare market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Metagenomics in Healthcare market?

Advances in sequencing technology and increasing demand for personalized medicine drive the market.

What are the major challenges facing the Metagenomics in Healthcare market?

High costs and complexity of metagenomics analysis are significant challenges.

Which regions are leading the Metagenomics in Healthcare market?

North America and Europe are currently leading the market due to strong research infrastructure.

Who are the top companies in the Metagenomics in Healthcare market?

Illumina, Thermo Fisher Scientific, and Qiagen are among the top companies in the market.

What future opportunities exist for the Metagenomics in Healthcare market?

Increasing applications in disease diagnosis and treatment will drive future growth.

How will technology impact the Metagenomics in Healthcare market?

Advances in AI and machine learning will improve data analysis and interpretation.

What is the current regulatory landscape for the Metagenomics in Healthcare market?

Regulatory frameworks are evolving to address issues like data privacy and security.

What is the future outlook for the Metagenomics in Healthcare market?

The market is expected to experience significant growth due to increasing adoption of metagenomics.

Metagenomics in Healthcare Market Metrics & Forecast Analysis 2033

Metagenomics in Healthcare by Application (Pharmaceutical Industries, Biotechnology Companies, Pathology Laboratories, Academic and Research Laboratories, Others), by Types (Sample Extraction Kits, Metagenomics Kits), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 17.1%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 17.1%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Metagenomics in Healthcare Market Size | CAGR 17.1 Forecast 2033

Metagenomics in Healthcare Market Metrics & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 17.1%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 17.1%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Metagenomics in Healthcare Market Overview

Metagenomics in healthcare refers to the application of metagenomics in medical and healthcare settings to understand the genetic makeup of microorganisms and their role in human health and disease. The Metagenomics in Healthcare market size is estimated to be around $1.4 billion in 2025, with a growth outlook that is promising due to increasing demand for personalized medicine and targeted therapies. The market forecast suggests a compound annual growth rate (CAGR) of 17.1% from 2026 to 2033, driven by industry expansion in the fields of genomics, epigenomics, and transcriptomics. The scope of the market includes various synonyms such as microbiome analysis, microbial genomics, and genomic medicine.

Loading chart…

The growth of the Metagenomics in Healthcare market is driven by several key forces, including technology shifts such as advances in next-generation sequencing, regulations such as the increasing need for regulatory compliance, and consumer behavior such as the growing demand for personalized medicine. The largest region in the market is North America, while the fastest-growing region is Asia-Pacific. The market is expected to be shaped by competitive intensity, with key players such as Illumina, Thermo Fisher Scientific, and Qiagen competing for market share. Overall, the Metagenomics in Healthcare market is poised for significant growth in the coming years, driven by its potential to transform the field of medicine and improve human health outcomes.

Report Overview

Report Attribute	Details
Market size value in 2025	12.60 million
Revenue forecast in 2033	44.55 million
Growth rate	CAGR of 17.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Illumina; QIAGEN; PerkinElmer; Thermo Fisher Scientific; Oxford Nanopore Technologies
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Metagenomics in Healthcare market is poised for significant growth, driven by factors such as advancements in sequencing technologies and increasing demand for personalized medicine. The growth forecast for the Metagenomics in Healthcare market size is promising, with the industry expected to expand rapidly over the next few years.

Growth Drivers2 items

Advances in next-generation sequencing technologies have reduced the cost and increased the speed of metagenomic analysis, making it more accessible to researchers and clinicians.

The growing awareness of the importance of the human microbiome in health and disease has led to increased investment in metagenomics research, driving growth in the Metagenomics in Healthcare market.

Restraints2 items

The high cost of metagenomic analysis and the need for specialized expertise and equipment are significant restraints on the adoption of metagenomics in healthcare, limiting the growth forecast for the Metagenomics in Healthcare market size.

The lack of standardization in metagenomic data analysis and interpretation is a major challenge, hindering the widespread adoption of metagenomics in healthcare and impacting the Metagenomics in Healthcare market.

Opportunities2 items

The increasing demand for personalized medicine and targeted therapies has created opportunities for metagenomics to play a key role in the development of novel treatments and diagnostics, driving growth in the Metagenomics in Healthcare market.

The growing recognition of the importance of the microbiome in health and disease has led to new opportunities for metagenomics research and development, with the potential to expand the Metagenomics in Healthcare market size.

Challenges2 items

The integration of metagenomic data with electronic health records and other healthcare systems is a significant challenge, requiring the development of new technologies and infrastructure to support the growth of the Metagenomics in Healthcare market.

The need for regulatory frameworks to govern the use of metagenomic data in healthcare is a major challenge, with the potential to impact the growth forecast for the Metagenomics in Healthcare market size if not addressed effectively.

Market Segmentation

Loading chart…

The Metagenomics in Healthcare segmentation by application is a crucial aspect of understanding the market dynamics. This segment is further divided into subtypes, including infectious disease diagnosis, cancer research, neurological disorders, and other applications. Each of these subtypes contributes to the overall Metagenomics in Healthcare market size, with infectious disease diagnosis holding a significant share. The application segment is expected to drive the market growth due to the increasing adoption of metagenomics in disease diagnosis and treatment.

The types segment in the Metagenomics in Healthcare market includes sequencing technologies and bioinformatics tools. Sequencing technologies, such as next-generation sequencing, are widely used in metagenomics research, while bioinformatics tools are essential for data analysis and interpretation. The types segment is critical in understanding the market taxonomy, as it helps identify the key technologies and tools driving the market growth. The increasing demand for sequencing technologies and bioinformatics tools is expected to contribute significantly to the overall market size.

Metagenomics in Healthcare Segmentation Breakdown9 items

Application

Pharmaceutical Industries

Biotechnology Companies

Pathology Laboratories

Academic and Research Laboratories

Others

Types

Sample Extraction Kits

Metagenomics Kits

Regional Insights

Loading chart…

The Metagenomics in Healthcare market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of metagenomics technologies, investments in healthcare infrastructure, and a growing ecosystem maturity.

Key drivers for North America include policies supporting genomics research, a mature infrastructure for healthcare and research, and a high level of demographics awareness about metagenomics. In Europe, drivers include investments in research and development, a strong ecosystem of pharmaceutical and biotechnology companies, and adoption of metagenomics in clinical settings. Asia Pacific is driven by demographics, with a large and growing population, increasing infrastructure development, and policies supporting healthcare innovation.

Latin America and Middle East & Africa are also expected to contribute to the Metagenomics in Healthcare market growth, with key drivers including adoption of metagenomics technologies, investments in healthcare infrastructure, and growing ecosystem maturity. The regional forecast indicates that these regions will play an increasingly important role in the global metagenomics market, driven by policies supporting healthcare innovation and demographics.

Competitive Landscape

The Metagenomics in Healthcare market is moderately consolidated, with a mix of global players and local companies competing on factors like pricing, distribution, and product innovation. The Metagenomics in Healthcare competitive landscape is characterized by key competitive levers such as certifications, regulatory approvals, and strategic partnerships. Global players are driving growth, while local companies focus on regional expansion and customization.

Companies in this market employ various strategies, including M&A, partnerships, and product launches, to differentiate themselves. However, they face challenges like margin pressure, compliance costs, and supply chain risks. To stay competitive, companies focus on technology, service model, and channel strength. The following companies are notable for their strategic focus:

Illumina: regional expansion

QIAGEN: vertical integration

PerkinElmer: premium pricing

Thermo Fisher Scientific: OEM tie-ups

Oxford Nanopore Technologies: innovation pipeline

Illumina: local manufacturing

Key Metagenomics in Healthcare Companies5 items

Illumina

QIAGEN

PerkinElmer

Thermo Fisher Scientific

Oxford Nanopore Technologies

Market Ecosystem

The Metagenomics in Healthcare ecosystem encompasses a complex network of stakeholders, spanning upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three key tiers: upstream, where raw materials and components are sourced; midstream, where technology providers and integrators add value; and downstream, where channels and end users ultimately capture value. The creation and capture of value within this ecosystem are deeply intertwined, with each participant relying on others to deliver high-quality products and services.

Technology providers — develop metagenomics platforms

System integrators / EPCs — integrate metagenomics solutions

Distributors / channel partners — supply metagenomics products

Service providers / after-sales — offer support and maintenance

End users / buyers — utilize metagenomics services

Regulators/standards bodies — set metagenomics standards

Data/analytics providers — provide insights and analytics

The flow of value within the Metagenomics in Healthcare ecosystem is influenced by various control points, including regulators and standards bodies that dictate the adoption of metagenomics technologies. Dependency risks, such as input constraints and approvals, can also impact the ecosystem. Furthermore, switching costs and interoperability requirements may pose challenges for end users. As the ecosystem differs by region, with varying regulatory frameworks and market conditions, participants must navigate these complexities to succeed in the Metagenomics in Healthcare ecosystem. A thorough value chain analysis is essential to understanding these dynamics and identifying opportunities for growth and collaboration.

Recent Industry Insights

The Metagenomics in Healthcare industry has witnessed significant developments over the last 12-18 months, shaping the current Metagenomics in Healthcare industry trends. Recent partnerships between leading biotechnology firms and research institutions have accelerated the discovery of novel therapeutic targets and diagnostics. Notable mergers and acquisitions have also led to the consolidation of expertise and resources, driving innovation in the field.

Furthermore, the launch of advanced next-generation sequencing technologies and artificial intelligence-powered analytics platforms has enhanced the accuracy and efficiency of metagenomic analysis. Regulatory changes, such as the updated guidelines for the use of metagenomics in clinical trials, have also contributed to the growth of the industry. Additionally, funding rounds and expansions have provided necessary support for startups and research initiatives, fostering a shift in consumer and enterprise trends towards personalized medicine and preventive care.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Metagenomics in Healthcare market outlook. The market attractiveness is high due to the increasing adoption of metagenomics in disease diagnosis and treatment. The competitive intensity is moderate, with key players focusing on innovation and partnerships to stay ahead. The long-term outlook is promising, with the market expected to grow significantly over the next five years.

The innovation landscape is rapidly evolving, with advancements in next-generation sequencing and bioinformatics driving growth. However, the demand–supply balance is a key concern, with a shortage of skilled professionals and high infrastructure costs. Key risk factors include regulatory challenges and the need for standardized protocols. Overall, the Metagenomics in Healthcare market outlook is positive, with opportunities for growth and investment in this emerging field.

11 items

1. Executive Summary

2. Metagenomics in Healthcare Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Metagenomics in Healthcare Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Metagenomics in Healthcare Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Pharmaceutical Industries

6.1.2. Biotechnology Companies

6.1.3. Pathology Laboratories

6.1.4. Academic and Research Laboratories

6.1.5. Others

6.2. Global Metagenomics in Healthcare Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Sample Extraction Kits

6.2.2. Metagenomics Kits

6.3. Global Metagenomics in Healthcare Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Metagenomics in Healthcare Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Metagenomics in Healthcare Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Metagenomics in Healthcare Market Competition by Key Manufacturers

8.1. Global Metagenomics in Healthcare Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Metagenomics in Healthcare: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Illumina

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. QIAGEN

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. PerkinElmer

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Thermo Fisher Scientific

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Oxford Nanopore Technologies

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Metagenomics in Healthcare Market

Figure 4: Global Metagenomics in Healthcare Market: Drivers

Figure 5: Global Metagenomics in Healthcare Market: Challenges

Figure 6: Global Metagenomics in Healthcare Market: Trends

Figure 7: Global Metagenomics in Healthcare Market: Opportunity

Figure 8: Global Metagenomics in Healthcare Market: Restraint

Figure 9: Global Metagenomics in Healthcare Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Metagenomics in Healthcare Market Value (USD Million) By Region

Figure 15: Global Metagenomics in Healthcare Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Metagenomics in Healthcare Market Value (USD Million) By Region

Figure 23: Global Metagenomics in Healthcare Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

63 items

Table 1: Market Segmentation Analysis

Table 2: Global Metagenomics in Healthcare Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Metagenomics in Healthcare Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Metagenomics in Healthcare Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Metagenomics in Healthcare Market Value (USD Million) By Region

Table 10: Global Metagenomics in Healthcare Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Metagenomics in Healthcare Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Metagenomics in Healthcare Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Metagenomics in Healthcare Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Illumina Basic Information And Sales Area

Table 31: Illumina. Products Portfolio

Table 32: QIAGEN Basic Information And Sales Area

Table 33: QIAGEN. Products Portfolio

Table 34: PerkinElmer Basic Information And Sales Area

Table 35: PerkinElmer. Products Portfolio

Table 36: Thermo Fisher Scientific Basic Information And Sales Area

Table 37: Thermo Fisher Scientific. Products Portfolio

Table 38: Oxford Nanopore Technologies Basic Information And Sales Area

Table 39: Oxford Nanopore Technologies. Products Portfolio

Table 40: Global Market Value (USD Million) (2025-2032) By Application

Table 41: Global Market Share (%) By Application (2032)

Table 42: Global Market Value (USD Million) (2025-2032) By Types

Table 43: Global Market Share (%) By Types (2032)

Table 44: Global Metagenomics in Healthcare Market Value (USD Million) By Region

Table 45: Global Metagenomics in Healthcare Market Share (%) By Region (2025-2032)

Table 46: North America Market Value (USD Million) (2025-2032) By Country

Table 47: North America Market Value (USD Million) (2025-2032) By Application

Table 48: North America Market Value (USD Million) (2025-2032) By Types

Table 49: Europe Market Value (USD Million) (2025-2032) By Country

Table 50: Europe Market Value (USD Million) (2025-2032) By Application

Table 51: Europe Market Value (USD Million) (2025-2032) By Types

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 53: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 55: South America Market Value (USD Million) (2025-2032) By Country

Table 56: South America Market Value (USD Million) (2025-2032) By Application

Table 57: South America Market Value (USD Million) (2025-2032) By Types

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 59: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 61: Research Programs/Design For This Report

Table 62: Key Data Information From Secondary Sources

Table 63: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Metagenomics in Healthcare Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.60 million
Revenue forecast in 2033	44.55 million
Growth rate	CAGR of 17.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Illumina; QIAGEN; PerkinElmer; Thermo Fisher Scientific; Oxford Nanopore Technologies
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options